https://rijournals.com/scientific-and-experimental-sciences/

RESEARCH INVENTION JOURNAL OF SCIENTIFIC AND EXPERIMENTAL SCIENCES 3(1):6-11, 2024

©RIJSES Publications ISSN: 1597-2917

Biologics and Biosimilars: Advancements, Challenges, and Therapeutic Applications

[1]Joseph Obiezu Chukwujekwu Ezeonwumelu, [2]Uhama Kingsley Chukwuka, [3]Ugwu Okechukwu Paul-Chima, [3]Alum Esther Ugo, [4]Ugwuanyi Anthony Chukwudi and [5]Tambwe Patrick Rodrigue

[1]Department of Clinical Pharmacy and Pharmacy Practice, Kampala International University Western Campus, Uganda.
[2]Department of Biochemistry, Faculty of Applied Natural Sciences, Enugu State University of Science and Technology, Nigeria.
[3]Department of Publication and Extension Kampala International University Uganda.
[4]Department of Microbiology Ebonyi State University Abakaliki, Nigeria.
[5]Department of Public Health Kampala International University Uganda.
Email: kingsley.uhama@esut.edu.ng

ABSTRACT

Biologics, derived from living cells, have revolutionized the treatment of chronic and complex diseases such as cancer, autoimmune disorders, and metabolic diseases. These complex molecules often exhibit superior efficacy and safety profiles compared to traditional chemical drugs, owing to their unique pharmacologic mechanisms and biophysical properties. The increasing demand for biologics has also spurred the development of biosimilars, cost-effective versions that promise to alleviate the financial burden on healthcare systems. Despite their benefits, biologics and biosimilars face significant manufacturing, regulatory, and economic challenges. This paper explores the definition, characteristics, and therapeutic applications of biologics, alongside the intricate processes involved in their production and purification. It also delves into the regulatory landscape governing biologics and biosimilars, highlighting the approval processes and future directions for innovation and accessibility in this rapidly evolving field.

Keywords: Biologics, Biosimilars, Therapeutic proteins, Monoclonal antibodies, Cytokines and Growth factors

INTRODUCTION

Biologics, a class of pharmaceuticals derived from living cells, have emerged as a pivotal component in modern medicine. Unlike traditional chemical drugs, biologics operate through unique pharmacologic mechanisms and exhibit superior biophysical properties, making them highly effective for treating various chronic and complex diseases [1-3]. These include conditions such as metabolic disorders, autoimmune diseases, and cancers, where biologics have often demonstrated better healthcare outcomes [4-7]. The nature of biologics—being derived from biological systems—lends them a complexity that chemical drugs do not possess. This complexity allows for highly specific therapeutic applications, often with fewer side effects and reduced toxicity. The U.S. Food and Drug Administration (FDA) defines biologics broadly, encompassing products like vaccines, blood components, allergenics, somatic cells, gene therapies, and recombinant therapeutic proteins [8-9]. These products can be composed of sugars, proteins, nucleic acids, or complex combinations thereof, or even living entities such as cells and tissues. The increasing reliance on biologics in healthcare has spurred a demand for more affordable alternatives, known as biosimilars. Biosimilars are essentially "copy" versions of biologics that are developed to be highly similar to, and have no clinically meaningful differences from, their reference biologics. This growing segment of the pharmaceutical market highlights the need for cost-effective therapeutic options without compromising on efficacy or safety [10-13]. Despite their significant therapeutic advantages, the development and production of biologics and biosimilars pose substantial challenges. These include complex manufacturing processes, rigorous regulatory requirements, and economic considerations [14-16]. The journey from discovery to patient administration involves intricate cell culture techniques, sophisticated purification processes, and stringent approval protocols to ensure the highest standards of safety and efficacy [17]. As biologics continue to expand their footprint in the pharmaceutical

landscape, it is crucial to understand their development, regulatory pathways, and therapeutic applications. This paper aims to provide a comprehensive overview of biologics and biosimilars, exploring their defining characteristics, historical development, manufacturing complexities, regulatory frameworks, and potential future directions [1]. Through this exploration, we seek to illuminate the transformative impact of biologics on healthcare and the ongoing efforts to enhance their accessibility and affordability [1-6].

Biologics

Importantly, biologics yield better healthcare outcomes for certain diseases than chemical drugs because they work via different pharmacologic mechanisms and have superior biophysical properties. One key aspect is that biologics can be utilized for highly specific therapy categories compared to traditional drugs [7-9]. Derived from living cells, biologics may also be associated with fewer side effects and less toxicity. Despite being more complex, biologics are a growing segment of the pharmaceutical market due to their increased development to treat chronic disease areas such as metabolic diseases, autoimmune diseases, and cancers. Despite being a new area in pharmacy, there is already a large demand for cost-saving "copy" versions of biologics [8]. These are called biosimilars. Biologics are substances derived from biological systems and, thereby, tend to be more complex than drugs synthesized through a chemical process [5]. Examples of biologics include therapeutic proteins that are the product of living beings and complex mixtures such as stem cells. The Food and Drug Administration (FDA) definition of biologics clearly illustrates this idea: "Biological products include a wide range of products such as vaccines, blood and blood components, allergenics, somatic cells, gene therapy, tissues, and recombinant therapeutic proteins [7-9]. Biologics can be composed of sugars, proteins, nucleic acids, or complex combinations of these substances, or they may be living entities such as cells and tissues."

Definition and Characteristics

A biologic, also known as a biological medical product, defines a substance that is derived from a living organism and has a broad array of functions [1-5]. The US Food and Drug Administration (FDA) categorizes biologics as products derived from living sources that are genetically engineered or manufactured via complex manipulations. For example, the blood, plasma, and clotting factors derived from human donors or animals, and stem cell, antibody, or vaccine products manufactured using biotechnological and/or advanced technologies are biologics. Biologics often have high potency and can only exhibit biological effects in humans or animals [8-11]. Due to the unique nature of biologics, proteins and amino acids, which are the primary components of many biologics, are the main focus in this review [8-10]. The term biologic, also known as a biological medical product, defines a substance that is derived from a living organism and has a broad array of functions. Biologics are used to treat various conditions including cancer, arthritis, and AIDS. Biologics are often one of the most expensive types of drugs, costing thousands of dollars per treatment. Moreover, biosimilars and advanced therapy medicinal products (ATMPs) are two subcategories of biologics. The development of robust, appropriate, and reliable analytical methods for the characterization of biologic drugs is of great importance during their development, control, and release stages 1-6].

History and Development

In its ongoing efforts to reduce the cost of prescription drugs, the administration has prioritized the approval of alternative biosimilar products [9]. Over the years, there has been significant progress in the development of biosimilars and the number of biosimilars approved for supreme biologics has been increasing [11-13]. The story of biologics and biosimilars begins in the 1980s and runs up to the present time. Biochemical advances, approvals, and discussions guide the process. These issues help to set into a clearer picture the serious problems in the production, structure, and licensing of biosimilars and their effects. In this review, an important part of the story, the general and legal aspects of biosimilars, are reviewed. This article also assesses the clinical requirements, development, and regulatory processes [14-17]. Furthermore, this article provides health-related and economical consequences and guidance. Biological medicines are one of the most important treatment options for a wide range of conditions, including cancer, diabetes, rheumatoid arthritis, inflammatory bowel diseases, psoriasis, macular degeneration, and some rare diseases. Some of the best-selling products in the history of the drugs market are biological medicines [1]. However, these medicines tend to be expensive (except for some insulin and products established for a long time). Today, it is not unusual for a biologic to cost around $10,000 or higher for typical treatment needs for a single patient annually. Since many biologics are used for chronic disease with annual expense that costs well over $10,000 and patients need treatments over many years, not only the individuals but also the healthcare management and economy being affected by cost side of biologics at the same time. But when the patents of these biologics run out, biological products can compete with reference biologics on the same terms as generics [1-5].

Biologics Manufacturing

Biologic drugs must be biologically active, and it has proved difficult to produce active biological products. Inactivation of particular biological products in specific ways often provides for biologics with no or very low biological activity [6]. Purity is wanted because of toxicity, contaminants often in the case of living cells, not just the specific product itself but also the other products. For example, the toxic effects of endotoxin and other

contaminants are well known. Highly purified product is wanted in the case of product intended for human use (e.g., up to 100% for DNA and RNA, protein and 90-99% for protein) [7]. The cellular debris created during cell death and other product release can be high (10(6) per liter of culture medium). The bioreactor environment is also very harsh. Large cells with the requirement for very high density cultures are commonly used. These cells are easily subject to lysis. High viscosity, due to the high concentration of the biologic product and other cellular debris, can lead to problems in mixing and aeration during cell maintenance [8]. Large volumes of media are often used (5-25 L in most cases per 1 liter of final product). Cells, and in some cases the biologic product, are also sensitive to nutrient depletion. However, the generation of small and large biologic products is particularly impacted by the nature of the animal cell culture system. Animal cells have a set number of organelles per cell and can only generate a set number of functional organelles. Additionally, these organelles are not generally present in large numbers in the cell. The production of biologic drugs is significantly more complicated and difficult when compared to small molecule or chemical drug production [11]. This complexity is due to the higher order nature of biologics, which is normally associated with those of living organisms. In general, biologic drugs can only be produced in living cells using relatively complex and almost 'ineffable' living cell machinery that includes processes such as metabolic transformation and complex purification methods. The traditional methods of animal cell culture were first routine operations in many industrial fermenters used to produce biologics [11].

Cell Culture Techniques

Recently developed biotechnological advances, such as native strains, have allowed us to establish serum-free medium formulations from loosely defined medium, from laboratory, industrial bioreactor, or pharmaceutical-grade material that can be obtained and exploited to obtain highly productive and accelerated growth characteristics [1-5]. Another platform for the production of protein therapeutics involves the use of transgenic animals to produce the biopharmaceuticals directly in their milk. One possible way to produce proteins and hormones is by using recombinant technology in in vitro animal cell culture [5-9]. The technology offers a safe and reliable process to produce biologic-based products. Cell culture production has advantages over microorganism fermentation processes because eukaryotic microorganism hosts (i.e., yeast and fungi) may not express specific mammalian proteins due to post-translational modifications. Even when the expressed molecule is the same, the same glycan structures will be different. Cell culture technologies can be used to produce monoclonal antibodies, viruses, vaccines, and many other protein products [10-13].

Purification Processes

The products derived from recombinant expression systems will be in complex mixtures with components such as by-products from the expression system, host cell proteins which might have been produced as part of the product (e.g., a fusion protein), DNA, bacterial endotoxins, growth media components, chromatographic support residuals, and viral particles [11-16]. Impurities arising from expression systems generally fall into four types: product-related impurities, process-related impurities, product degradation products, and non-product-related impurities. The type and complexity of expression system-derived impurities found can be very different due to the biologic molecule being produced and the culture conditions used [3-7]. Consequently, the choice of which technologies to apply to the purification of a biologic molecule will depend on the characteristics of the molecule and the type of expression system used. Purification processes enable the isolation of the desired protein while at the same time ensuring that it retains its biological activity, is free of trace contaminating substances that might potentially be toxic, and has a high degree of purity [8-9]. The challenge in the purification of many biologic molecules is the ability to capture and selectively purify the molecule with minimal changes in its native structure. Designing a purification process can be challenging not just because of the large size of some of these biologic molecules, but also because they can be very sensitive to a range of process conditions including temperature, pH, ionic strength, adsorption, air-liquid interfaces, high shear, and oxidation effects. Careful consideration of the process design is important at an early stage of the development of the product to avoid potential irreversible damage and a loss of biological activity [11-13].

Regulation of Biologics

Since biologics are registered patents, there are many difficulties in developing biosimilars, including the scientific and safety issues, registration techniques, and economic factors [3-7]. Regulatory agencies such as the European Medicines Agency (EMA), U.S. Food and Drug Administration (FDA), and World Health Organization (WHO) have established final biosimilar regulation guidelines, drafts, or concepts. Several admission agencies such as Agence Francaise de Securite Sanitaire des Produits de Sante (AFSSAPS), Health Canada, and Therapeutic Goods Administration (Australia) have reviewed, consulted, and participated in the final guidelines. Due to the similarities and differences between the biologics and biosimilars regulations, countries applied different concepts and new laws [5-9]. The approach for the regulations of biologics and biosimilars is declining from the simplest of advanced products. The patient's safety and their benefits are the main purpose in the simplest literature of life laws. Biologics are complex biological products that are manufactured in living cells and are very sensitive to the environment. They have both post-translational modifications and higher-order structures that are difficult to characterize and

reproduce in other stages [10-14]. Although the concept of metabolism and biosimilarity existed for many years, a regulatory science-governed scientific approach to assess the similarities to their originators was not established until the first biosimilar, Omnitrope, was approved in 2006. Biologics are regulated in different manners in various countries, based on their scientific governance, historic pharmaceutical or political background. This chapter focuses on biologic regulations generally, based on the reference products, the naming and naming policies, and guideline documents and case studies on several issues during the biosimilar development [15-17].

FDA Approval Process

The approval process for biologics can be summarized in the production of clinical evidence for the determination of efficacy, dose-finding, benefits and risks, its side effects, patient selection, and a safe way of administration. After this process, the FDA reviews the collected information and evaluates the evidence for the determination of benefits and risks [7]. Subsequently, they can approve the clinical evidence on the basis that the benefits of the product outweigh risks in the population of the intended use [9]. This information is then used to develop labels which explain to healthcare providers how to use the drug and guide patients receiving essential information. The product will then be formally approved and launched by the manufacturers to the relevant market, being parallel to the relevant price and reimbursement negotiations. After approval, biologics remain under FDA surveillance. Approval of biologics in the United States requires the pre-approval of the product's safety and efficacy by the FDA. The review and approval process of biologics was established in 1902 by the Biologics Control Act and changed in 1997 by the Food and Drug Administration Modernization Act (FDAMA). It was further modified in 2002 and 2007 by the Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA) and in 2010 through the Biologics Price Competition and Innovation Act, which wanted to replace the numerous non-interchangeable state laws. Also, USDA regulations state in 9 CFR 101.6 that labeling in a biologics' package must contain a validated warning or caution statement regarding animal and human safety [11].

Biosimilar Pathway

In 2010, the Biologics Price Competition and Innovation Act (BPCIA) was established to create a biosimilar pathway in the United States and include the process of approval for biologics that are "highly similar" to, and have no clinically meaningful differences from, an existing FDA-approved reference product. The biosimilar nature of a biologic is a complex novel concept, and numerous aspects such as clinical development, data requirements, and state regulations must be further regulated to form an effective statutory framework. The BPCIA also opened the door for related cost savings in healthcare and economic benefits by creating a competitive market for biological products. To date, the FDA has approved multiple biosimilars for various disease conditions. The US is moving towards greater use of biosimilars but still lags in comparison to Europe [8].

Therapeutic Applications of Biologics

Combining the focus channels of a research team so that a common purpose is directed to a common problem can shorten the time that the research takes and increase the probability of success [7]. A major result of the more rapid research and development cycles, which can be directed in biotechnology, is the ability to improve existing drugs, such as enzymes which had their therapeutic usefulness recognized before the biotechnology revolution, and to shorten the therapeutic development cycles, such as vaccines, which are a critical need when a new epidemic threatens the world's population [8]. In fact, besides the growing list of molecules that biotechnology has identified that can help prevent, treat, or cure disease, the shorter development times, existent for many types of biotechnology-derived product, mean that patients can be treated with these products when it can be proved that they are safe and efficacious. Biotechnology has opened the door to new ways to diagnose and treat illness as well as prevent disease in the first place. In 1975, no biopharmaceuticals were on the market in the United States [6]. Today, over 170 are utilized in almost every healthcare setting. From the time a genetic trigger for a disease has been identified, it can be only a few months or less for the scientific base to help create a product that can treat the disease, especially using recombinant DNA techniques. In the U.S., two basic concepts govern the development of therapeutics: the structure/function principle, which is generally applicable to all drug products, and the use of recombinant DNA techniques, which is applicable only to biotechnology-based products known as biotechnology-derived products, or more informally, biologics [11].

Monoclonal Antibodies

Clinical use of antibodies started in the early 1980s, for example, with the introduction of Gravezumab, the first monoclonal antibody which was binding IgE, responsible for allergic anaphylaxis. The century's USA Food and Drug Administration (FDA) approval of monoclonlonal antibodies in the treatment of diseases was in 1997 with the CD20 directed Rituximab for non-Hodgkin lymphoma [7]. Currently, around 1000 clinical trials are being conducted focusing on a range of monoclonal antibodies covering a broad spectrum of diseases from rheumatoid arthritis to psoriatic arthritis and others. A large number of monoclonal antibodies cover neoplasms, usually interfered with common oncological signaling pathways of growth and metastasis. There are both combative and protective strategies in the field [9]. Antibodies are natural molecules in humans that are produced by B-lymphocytes in immune reactions for an immunological counterattack. In biotechnology, to induce the production

of large amounts of antibodies, laboratory incubation of immune cells in cultures or, more specifically, by producing identical or adapted molecules by genetic manipulation of the sequence are used. In general, three types of antibody-based agents exist in use as pharmaceuticals: polyclonal antibodies, monoclonal antibodies, and fragments of monoclonal antibodies [12]. The development of monoclonal antibodies started as a field of basic research in the 1970s and broadened its scope along with the technology advances.

Cytokines and Growth Factors

One of the most well-known cytokines is interferon, discovered in the early 1950s by Isaacs and Lindenmann. Growth factors support cellular growth and proliferation. Erythropoietin (EPO) is an example of such factors acting on specific cells such as erythrocyte precursors [13]. Given the broad spectrum of biological activities associated with each cytokine and their efficiency in the human body, cytokines and growth factors are widely used in immunotherapy. Although the existing cytokines and growth factors are effective in the treatment of various diseases, the cost of these products is still high [14]. Cytokines and growth factors are proteins responsible for cell signaling that play an important part in immunoregulation, hematopoiesis, and erythropoiesis [16]. These substances can be used to treat different types of conditions such as inflammatory disorders and cancer. However, the existing cytokines and growth factors can be expensive, requiring cheaper alternatives. Biobetters, including biosimilars, are possible candidates of such a type. Cytokines, produced by immune system cells, are signaling proteins involved in the communication among cells. The main function of these signaling proteins is to modulate the activities of non-specialized cells [12].

Challenges and Future Directions

In the process of drug development, manufacturing, approval, pricing, and regulation, various problems, such as the complex process of quality control, dependence on living systems for production, potential health risks to patients, shortage of drugs, and affordability, among others, are brought to the fore [1-4]. In fact, controversy over the properties, benefits, and costs of innovative biotechnology drugs and related biosimilars and generic drugs has arisen among researchers and policymakers as well as between the pharmaceutical industry and consumer groups. There is an urgent need to develop innovative biotech drugs and biosimilars and to promote the entry of these products into the pharmaceutical market [5-7]. Regulatory reform should also be discussed in parliamentary and social circles to ensure the health and welfare of the people. Over time, the number and complexity of approved biotechnology-derived drugs and related biosimilars and generic drugs has grown. Advances in biotechnological and chemical science and nanotechnology will contribute to this trend in the future [8-9]. Drug development, manufacturing, and marketing will become more complex and diverse. Therefore, proper regulation and fair and appropriate biotechnologically derived drugs, biosimilars, and chemically synthesized generic drugs, as well as intellectual property management, are necessary and important.

CONCLUSION

Biologics represent a groundbreaking advancement in the pharmaceutical industry, offering targeted therapies for a range of complex diseases with fewer side effects and improved patient outcomes compared to traditional drugs. The growing market for biologics underscores their therapeutic potential, yet also brings to light significant challenges in their development, production, and regulation. The emergence of biosimilars provides a promising avenue for reducing healthcare costs and increasing patient access to essential biologic therapies. However, ensuring the safety, efficacy, and affordability of these complex molecules requires continued innovation in biotechnological methods and stringent regulatory oversight. As biologics and biosimilars continue to evolve, the industry must navigate the complexities of manufacturing processes, regulatory requirements, and market dynamics. Advances in biotechnological research, coupled with robust regulatory frameworks, will be crucial in addressing these challenges and fostering the development of new biologics and biosimilars. The future of biologic therapies holds immense potential for transforming patient care, with ongoing efforts to enhance their accessibility, affordability, and therapeutic efficacy.

REFERENCES

1. Menon, D. & Bril, V. (2022). Pharmacotherapy of generalized myasthenia gravis with special emphasis on newer biologicals. Drugs. springer.com
2. Klein, S. L. & Morgan, R. (2020). The impact of sex and gender on immunotherapy outcomes. Biology of sex differences. springer.com
3. Vora, L. K., Gholap, A. D., Jetha, K., Thakur, R. R. S., Solanki, H. K., & Chavda, V. P. (2023). Artificial intelligence in pharmaceutical technology and drug delivery design. Pharmaceutics, 15(7), 1916. mdpi.com
4. Ruiz-Alonso, S., Lafuente-Merchan, M., Ciriza, J., Saenz-del-Burgo, L., & Pedraz, J. L. (2021). Tendon tissue engineering: Cells, growth factors, scaffolds and production techniques. Journal of Controlled Release, 333, 448-486. sciencedirect.com
5. Gülsen, A., Wedi, B., & Jappe, U. (2020). Hypersensitivity reactions to biologics (part I): allergy as an important differential diagnosis in complex immune-derived adverse events. Allergo journal international. springer.com

6. Ten Bergen, L. L., Petrovic, A., Krogh Aarebrot, A., & Appel, S. (2020). The TNF/IL-23/IL-17 axis—Head-to-head trials comparing different biologics in psoriasis treatment. Scandinavian journal of immunology, 92(4), e12946. wiley.com
7. Tanaka, Y. (2021). Recent progress in treatments of rheumatoid arthritis: an overview of developments in biologics and small molecules, and remaining unmet needs. Rheumatology. oup.com
8. Nasim, N., Sandeep, I. S., & Mohanty, S. (2022). Plant-derived natural products for drug discovery: current approaches and prospects. The Nucleus. springer.com
9. Overbeck, N., Nagvajara, G. M., Ferzoco, S., May, B. C. H., Beierschmitt, A., & Qi, S. (2020). In-vivo evaluation of a reinforced ovine biologic: a comparative study to available hernia mesh repair materials. Hernia, 24, 1293-1306. springer.com
10. Nataraj, B. H., Ali, S. A., Behare, P. V., & Yadav, H. (2020). Postbiotics-parabiotics: The new horizons in microbial biotherapy and functional foods. Microbial cell factories. springer.com
11. Qi, J., Ou, H., Liu, Q., & Ding, D. (2021). Gathering brings strength: How organic aggregates boost disease phototheranostics. Aggregate. wiley.com
12. Lin, Q., Lim, J. Y., Xue, K., Yew, P. Y. M., Owh, C., Chee, P. L., & Loh, X. J. (2020). Sanitizing agents for virus inactivation and disinfection. View, 1(2), e16. wiley.com
13. Pilely, K., Johansen, M. R., Lund, R. R., Kofoed, T., Jørgensen, T. K., Skriver, L., & Mørtz, E. (2022). Monitoring process-related impurities in biologics–host cell protein analysis. Analytical and Bioanalytical Chemistry, 414(2), 747-758. springer.com
14. Moleirinho, M. G., Silva, R. J., Alves, P. M., Carrondo, M. J., & Peixoto, C. (2020). Current challenges in biotherapeutic particles manufacturing. Expert opinion on biological therapy, 20(5), 451-465. tandfonline.com
15. Rao, V. A., Kim, J. J., Patel, D. S., Rains, K., & Estoll, C. R. (2020). A comprehensive scientific survey of excipients used in currently marketed, therapeutic biological drug products. Pharmaceutical Research. springer.com
16. Ahn, D. G., Shin, H. J., Kim, M. H., Lee, S., Kim, H. S., Myoung, J., ... & Kim, S. J. (2020). Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease 2019 (COVID-19). Journal of microbiology and biotechnology, 30(3), 313. nih.gov
17. Rawat, K., Kumari, P., & Saha, L. (2021). COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies. European journal of pharmacology. nih.gov

CITE AS: Joseph Obiezu Chukwujekwu Ezeonwumelu, Uhama Kingsley Chukwuka, Ugwu Okechukwu Paul-Chima, Alum Esther Ugo, Ugwuanyi Anthony Chukwudi and Tambwe Patrick Rodrigue (2024). Biologics and Biosimilars: Advancements, Challenges, and Therapeutic Applications. RESEARCH INVENTION JOURNAL OF SCIENTIFIC AND EXPERIMENTAL SCIENCES *3*(1):6-11.